2212 GMT - Pathology services provider Healius is in the recovery room, but Barrenjoey is skeptical that the company can reach performance targets laid out at its investor day yesterday. Healius wants to grow revenue at 6% and make a high-single-digit Ebit margin by FY 2027. Analyst Saul Hadassin says this implies Ebit growing at a compound annual rate of 120% from FY 2025-FY 2027. "While we anticipate an improvement in operating performance, this target looks difficult to deliver, particularly in light of looming cuts to VitB12/mid-stream urine tests," Barrenjoey says. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 27, 2025 18:12 ET (22:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.